Subscribe to RSS
Download PDF
DOI: 10.1055/s-0042-1758805
Not All Glittering Bone Lesions Are Gold: A Case of Sclerotic Bone Lesions with Elevated 68Ga PSMA and 99mTc HDP Uptake with No Signs of Malignancy
Abstract
Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography (68Ga PSMA PET/CT) outperforms CT and bone scintigraphy in terms of diagnostic accuracy for the primary staging of prostate cancer and has become widely used. However, 68Ga PSMA uptake is also encountered in nonprostatic tissue. We present a 63-year-old male with newly diagnosed high-risk prostate cancer who underwent bone scintigraphy with single-photon emission computed tomography/computed tomography (SPECT/CT), which showed inhomogeneous elevated uptake in sclerotic bone lesions in the pelvis. Likewise, 68Ga PSMA PET/CT revealed inhomogeneous uptake in the same areas. Subsequent biopsy revealed hyperplastic bone marrow without signs of malignancy. The patient underwent radical prostatectomy, and the prostate-specific antigen level dropped to less than 0.1 ng/mL.
Note
The patient was scanned and treated at Aalborg University Hospital, Aalborg, Denmark.
Authors' Contributions
Authors are credited in the presented order of authorship. Morten Bentestuen was responsible for the completion of the present case report, gathered data, drafted manuscripts and created all figures. Helle Damgaard Zacho supervised the process. Maria Carlsen Elkjær and Helle Damgaard Zacho revised drafts and accepted the final product.
Publication History
Article published online:
20 December 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Men Health 2018; 12 (06) 1807-1823
- 2 Hofman MS, Lawrentschuk N, Francis RJ. et al; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395 (10231): 1208-1216
- 3 Zacho HD, Pedersen SH, Petersen A, Petersen LJ. 68Ga-PSMA PET/CT uptake in the ureter caused by ligand expression in urothelial cancer. Clin Nucl Med 2020; 45 (01) e43-e45
- 4 Castello A, Lopci E. Incidental identification of osteoid osteoma by 68Ga-PSMA PET/CT. Eur J Nucl Med Mol Imaging 2018; 45 (03) 509-510
- 5 Artigas C, Otte FX, Lemort M, van Velthoven R, Flamen P. Vertebral hemangioma mimicking bone metastasis in 68Ga-PSMA ligand PET/CT. Clin Nucl Med 2017; 42 (05) 368-370
- 6 Merrild EH, Baerentzen S, Bouchelouche K, Buus S. Vertebral myeloma mimicking prostatic carcinoma metastasis in 68Ga-PSMA PET/CT. Clin Nucl Med 2017; 42 (10) 790-792
- 7 Vamadevan S, Le K, Bui C, Mansberg R. Incidental PSMA uptake in an undisplaced fracture of a vertebral body. Clin Nucl Med 2017; 42 (06) 465-466
- 8 Jochumsen MR, Madsen MA, Gammelgaard L, Bouchelouche K. Lumbar osteophyte avid on 68Ga-prostate-specific membrane antigen PET/CT. Clin Nucl Med 2018; 43 (06) 456-457
- 9 Sasikumar A, Joy A, Nanabala R, Pillai MR, TA H. 68Ga-PSMA PET/CT false-positive tracer uptake in Paget disease. Clin Nucl Med 2016; 41 (10) e454-e455
- 10 Petersen LJ, Zacho HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer Imaging 2020; 20 (01) 10